Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 9:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Feraheme Clear all
Completed Phase 2 Interventional Results available

Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers

NCT02141490
View directory record Official record
Conditions
Prostate Cancer, Bladder Cancer, Kidney Cancer
Interventions
Ferumoxytol, Magnetic Resonance Imaging (MRI)
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 25, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia

NCT01114139
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol, Placebo
Drug · Other
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
812 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
137
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 105 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Sep 25, 2026, 9:53 AM EDT
Terminated Early Phase 1 Interventional

Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer

NCT03280277
View directory record Official record
Conditions
Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Ferumoxytol
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Sep 25, 2026, 9:53 AM EDT
Terminated Phase 2 Interventional Results available

Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors

NCT00659126
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain, Primary Brain Neoplasm
Interventions
3 Tesla Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol, Gadolinium, High Field Strength Magnetic Resonance Imaging, Susceptibility Weighted Imaging
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 25, 2026, 9:53 AM EDT
Terminated Phase 1 Interventional

Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy

NCT00769093
View directory record Official record
Conditions
Brain Neoplasms
Interventions
Ferumoxytol
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 25, 2026, 9:53 AM EDT
Completed Phase 3 Interventional

A Crossover Safety Study of Ferumoxytol Versus Placebo

NCT00255450
View directory record Official record
Conditions
Anemia
Interventions
ferumoxytol or placebo
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
41
States / cities
Mobile, Alabama • Phoenix, Arizona • Mountain View, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2008 · Synced Sep 25, 2026, 9:53 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Anti-biofilm Effects of Ferumoxytol (Feraheme) Using an in Situ Biofilm Demineralization Model

NCT03678012
View directory record Official record
Conditions
Dental Caries
Interventions
Ferumoxytol/Hydrogen peroxide, Hydrogen Peroxide, Water
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Indianapolis, Indiana • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Sep 25, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency Anemia

NCT04253626
View directory record Official record
Conditions
Pregnancy Related, Anemia, Iron Deficiency
Interventions
Ferumoxytol Injection [Feraheme], Ferrous Sulfate
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 25, 2026, 9:53 AM EDT
Withdrawn No phase listed Observational

High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases

NCT01973517
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Feraheme, Gadolinium-based contrast
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 25, 2026, 9:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging

NCT01815333
View directory record Official record
Conditions
Cancer of Lymph Node
Interventions
Feraheme, Magnetic Resonance Imaging (MRI)
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 25, 2026, 9:53 AM EDT
Withdrawn Not applicable Interventional

Diagnostic Accuracy of Ferumoxytol-Enhanced MRI for Detecting Lymph Node Metastases in Colorectal Cancer

NCT01983371
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Ferumoxytol, Magnetic Resonance Imaging
Drug · Other
Lead sponsor
Scott Potenta, MD, PhD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Sep 25, 2026, 9:53 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding

NCT04205266
View directory record Official record
Conditions
Anemia, Iron Deficiency, Heavy Menstrual Bleeding
Interventions
Ferumoxytol, Ferrous Sulfate
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Sep 25, 2026, 9:53 AM EDT
Recruiting Phase 2 Interventional

Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants

NCT05340465
View directory record Official record
Conditions
Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption
Interventions
Darbepoetin Alfa, Low Molecular Weight Iron Dextran, Ferumoxytol injection, Oral iron supplements
Drug
Lead sponsor
University of Washington
Other
Eligibility
Up to 3 Days
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 25, 2026, 9:53 AM EDT
Recruiting Phase 3 Interventional

Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients

NCT07461948
View directory record Official record
Conditions
Glioblastoma
Interventions
Biospecimen Collection, Chemical Exchange Saturation Transfer Magnetic Resonance Imaging, Diffusion-Relaxation Correlation Spectrum Imaging, Electronic Health Record Review, Ferumoxytol, Magnetic Resonance Imaging
Procedure · Other · Drug + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 25, 2026, 9:53 AM EDT
Terminated Phase 2 Interventional Results available

Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma

NCT03347617
View directory record Official record
Conditions
Glioblastoma
Interventions
Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pembrolizumab
Drug · Other · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 25, 2026, 9:53 AM EDT
Withdrawn Not applicable Interventional

Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas

NCT01663090
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Ferumoxytol
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 25, 2026, 9:53 AM EDT
Recruiting Phase 1 Interventional

Calculating Wall Shear Stress in Infant Pulmonary Veins

NCT06440408
View directory record Official record
Conditions
Pulmonary Vein Stenosis
Interventions
Ferumoxytol
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 25, 2026, 9:53 AM EDT
Active, not recruiting Phase 1 Interventional Results available

A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

NCT04900792
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
Ferumoxytol injection, Pharmacological ascorbate, External beam radiation therapy, Temozolomide
Drug · Radiation
Lead sponsor
Bryan Allen
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 25, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia

NCT01114217
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
103
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Sep 25, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease

NCT01052779
View directory record Official record
Conditions
Iron Deficiency, Anemia, Kidney Disease
Interventions
Ferumoxytol, Iron Sucrose
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Tempe, Arizona • Chula Vista, California • Mountain View, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 25, 2026, 9:53 AM EDT
Terminated Phase 2 Interventional Results available

MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation

NCT00659776
View directory record Official record
Conditions
Nervous System Diseases, Diagnostic Imaging
Interventions
Ferumoxytol
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 80 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 25, 2026, 9:53 AM EDT
Not listed Not applicable Interventional

Development and Validation of Advanced MRI Methods for Clinical Applications

NCT03264300
View directory record Official record
Conditions
Brain Tumor
Interventions
MRI
Other
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Sep 25, 2026, 9:53 AM EDT
Withdrawn Phase 4 Interventional

Safety Assessment of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)

NCT01151592
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Iron Sucrose
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 25, 2026, 9:53 AM EDT
Completed Phase 3 Interventional

Intravenous Infusions of Ferumoxytol Compared to Oral Ferrous Sulfate for the Treatment of Anemia in Pregnancy

NCT03657433
View directory record Official record
Conditions
Iron Deficiency Anemia of Pregnancy
Interventions
Ferrous sulfate 325mg, Ferumoxytol
Dietary Supplement · Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Sep 25, 2026, 9:53 AM EDT